# Glucotrack, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Glucotrack, Inc.). ## Overview Glucotrack, Inc. is a U.S.-based medical device developer focused on novel diabetes technologies. Its core program is the Glucotrack CBGM, an implantable continuous blood glucose monitor being developed for people with Type 1 diabetes and insulin-dependent Type 2 diabetes. ## Products & services • Glucotrack CBGM implantable continuous blood glucose monitor • Diabetes monitoring device development and clinical programs • FDA registration and regulatory development work • Product model iteration and next-generation CBGM design - **Implantable glucose monitoring devices** (0%) — The Glucotrack CBGM and related implantable continuous blood glucose monitoring technology for diabetes care. - **Clinical development services** (0%) — Clinical trial execution, testing, and development activities needed to advance the device toward commercialization. - **Regulatory and FDA readiness** (0%) — Work supporting FDA registration, documentation, and product approval preparation. - **R&D and product engineering** (100%) — Internal research, design, and engineering for new CBGM models and product candidates. - Glucotrack CBGM implantable continuous blood glucose monitor - Diabetes monitoring device development and clinical programs - FDA registration and regulatory development work - Next-generation CBGM models and product candidates ## Customers Glucotrack does not yet appear to have commercial customers because the CBGM has not been commercialized. Its eventual buyers are expected to be people with diabetes, especially Type 1 patients and insulin-dependent Type 2 patients, likely through healthcare providers and reimbursement channels. The company’s near-term stakeholders are clinical investigators, regulators, and financing partners that support development. - **Type 1 diabetes patients** (primary) — Future end users of the implantable CBGM who need continuous glucose data for insulin management. - **Insulin-dependent Type 2 diabetes patients** (primary) — Future end users who may benefit from continuous monitoring to improve glycemic control. - **Clinical and regulatory stakeholders** (secondary) — Hospitals, investigators, and regulators involved in trials, validation, and FDA registration. - **Capital providers** (primary) — Equity and debt investors funding development before commercialization. - Type 1 diabetes patients needing continuous glucose monitoring - Insulin-dependent Type 2 diabetes patients seeking long-term monitoring - Healthcare providers and endocrinology practices - Clinical trial participants and investigators - Regulators and reimbursement stakeholders influencing adoption ## Geography Glucotrack is headquartered in the United States and its filings are on a U.S. reporting basis. The business currently appears centered on U.S.-based R&D, clinical, and regulatory work, with no disclosed commercial geographic revenue mix because the product has not been commercialized. Geography matters mainly through U.S. FDA oversight, domestic financing access, and the location of clinical development activities. - Headquartered in the United States - U.S. regulatory pathway is central to commercialization - Clinical and R&D activity appears U.S.-based - No disclosed country revenue mix because product is pre-commercial - Future expansion depends on approval and market access ## Strategy The company’s strategy is to advance the Glucotrack CBGM through clinical development, FDA registration, and eventual commercialization. Near term, management is focused on preserving liquidity, raising capital, and funding the next stages of development while expanding clinical trial activity and product iterations. - **Clinical development of Glucotrack CBGM** (short-term) — Clinical evidence is required to support regulatory approval and future adoption. - **FDA registration and regulatory progress** (short-term) — Regulatory clearance is the gate to commercialization and revenue generation. - **Capital raising and liquidity preservation** (short-term) — The company is a going concern and needs external funding to continue operations. - Advance the implantable CBGM through clinical development - Complete FDA registration and regulatory milestones - Expand clinical trial activity and supporting personnel - Develop new CBGM models and product candidates - Raise capital through equity, debt, or collaboration deals ## Risks Glucotrack faces classic pre-commercial medtech risks: it has not yet generated product revenue, needs significant additional funding, and depends on successful clinical and regulatory execution. The company also disclosed substantial doubt about its ability to continue as a going concern, making financing availability a central business risk. - **Going concern and liquidity shortfall** [critical] — The company states current cash is not sufficient for the next twelve months and it needs external financing. - **Clinical and regulatory execution risk** [high] — Commercialization depends on successful trials and FDA registration, both of which can be delayed or fail. - **Financing and dilution risk** [high] — The company plans to fund operations through debt or equity, which may be unavailable or dilutive. - **Commercial adoption risk** [medium] — Even after approval, the implantable device must win physician and patient acceptance versus existing monitoring options. - No commercialization yet, so there is no operating revenue base - Going concern risk due to limited cash and ongoing losses - Clinical trial and FDA approval delays could push out launch - Future financing may be unavailable or highly dilutive - Medtech adoption risk if implantable monitoring is not accepted ## Accounting Glucotrack’s accounting is dominated by judgmental estimates typical of a development-stage company, especially fair value changes in derivative liabilities and stock-based compensation. Because it has no commercial revenue and is funding operations through equity-linked instruments, valuation of warrants, convertible notes, and financing costs can materially affect reported results. - **Derivative liabilities fair value** — Can materially swing quarterly net loss - **Stock-based compensation** — Raises reported operating costs without cash outflow - **Going concern estimates** — Affects financial statement presentation and investor risk assessment - **Convertible notes and warrant accounting** — Can affect equity, liabilities, and financing expense - Fair value changes in derivative liabilities affect other income/expense - Stock-based compensation is embedded in R&D and G&A costs - Convertible notes and warrant exchanges can create complex equity accounting - Going concern disclosures influence liquidity and estimate assumptions - No revenue recognition complexity yet because the product is pre-commercial --- *Last updated: 2026-04-28T20:11:38.931883+00:00*